A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys (Q88006648)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

A safety and immunogenicity study of immunization with hVEGF26-104/RFASE in cynomolgus monkeys (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Arjan W Griffioen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Tanja D de Gruijl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Madelon Q Wentink

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Henk M W Verheul

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Kenneth A Schafer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Susan McPherson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Richard J Early

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

5 March 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

2025-2032

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Role of the tumor stroma in resistance to anti-angiogenic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

The great escape; the hallmarks of resistance to antiangiogenic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Vaccination approach to anti-angiogenic treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Vaccine CIGB 247 is potentially safe for use as a novel therapeutic vaccine against cancer in Chlorocebus aethiops monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Total Chemical Synthesis of Biologically Active Vascular Endothelial Growth Factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

The novel adjuvant CoVaccineHT™ increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

Platelets Take Up the Monoclonal Antibody Bevacizumab

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.02.066

10.1016/J.VACCINE.2018.02.066

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29519591%20AND%20SRC:MED&resulttype=core&format=json